

Zinc Lozenges: Cold Cure or Candy? Solution Chemistry Determinations

George A. Eby¹

Received January 2004

Common colds were shortened by 7 days in a 1984 clinical trial using zinc gluconate throat lozenges each 2 h. Between then and 2004, 10 other double-blind, placebo-controlled clinical trials showed widely varying results. This re-analysis of these trials presents solution chemistry methods to elucidate differences in efficacy. Statistically significant correlation was shown between total daily dosages of positively charged zinc species and reductions in median ($p = 0.005$) and mean duration ($p < 0.02$) of common colds in these trials.

KEY WORDS: Zinc; zinc gluconate; zinc acetate; zinc lozenges; common cold; rhinovirus.

ABBREVIATIONS: biologically closed electric circuits (BCEC); intercellular adhesion molecule-1 (ICAM-1); positively charged zinc species at pH 7.4 (iZn); zinc acetate (ZA); zinc gluconate (ZG); zinc gluconate-glycine (ZGG); zinc gluconate-citrate (ZG-C).

INTRODUCTION

Common colds are self-limiting viral illnesses of the upper respiratory tract. Rhinoviruses, the main viruses found in common colds, cause scratchy throats which are followed by sneezing, runny nose, nasal congestion and other familiar symptoms [1]. No treatment has been proven to effectively reduce the duration of common colds.

Common colds result in millions of lost or impaired work and school days, with billion of dollars wasted on palliatives each year. A reliable, simple, side-effect free and cost effective method of reducing common cold duration would be important to the public and the economy.

Great promise for an effective treatment was first shown by Eby *et al.* [2] in 1984 with a 7-day mean reduction in durations of common colds with zinc gluconate (ZG) throat lozenges used each two wakeful hours. Eby described these effects as local, not systemic. Similar results rapidly followed with a 1987 report by the British Medical Research Council (MRC) Common Cold Unit [3].

Between 1987 and 2004 reductions in duration of common colds by zinc lozenges were reported in five additional double-blind, placebo-controlled clinical trials,

¹George Eby Research, 14909-C Fitzhugh Road, Austin, Texas 78736, Tel: +1-512-263-0805; Fax: +1-512-263-0805; E-mail: george.eby@starband.net

and null effects were reported in five others. By 2004, these contradictory later findings resulted in a loss of interest in this method of treating common colds.

In early efforts to explain some of these divergent results, analyzes by Eby showed a linear relationship between efficacy and Zn^{2+} ion availability from lozenges [4–6]. Later, analysis by Bakar *et al.* [7] demonstrated significant correlation between Zn^{2+} ion concentration and biological response from ZG lozenges tested, but no correlation between total zinc and biological response. Not considering the amount of active ingredient (positively charged zinc ions) in meta-analyzes by Jackson *et al.* [8, 9] and in the review by Macknin [10] resulted in no correlation being observed.

There remain seven positive studies, and undisputed multiple beneficial actions of positively charged zinc at 0.05–0.1 mM, which include antirhinoviral effects [4, 11], immunologic benefits [4, 12], cell membrane stabilization [13] and possible inhibition of intercellular adhesion molecule-1 (ICAM-1) activity [14]. No virologic or other beneficial action has been published for neutrally or negatively charged zinc species *in vitro*.

In this re-analysis of all published reports of double-blind, placebo-controlled clinical trials of zinc lozenges against the duration of common colds, the hypothesis that there is a direct correlation between daily dosage of all positively charged zinc species at physiologic pH from lozenges and reductions in duration of common colds was tested using solution chemistry methods. Consequently, this review is focused on the chemistry of the lozenges, and does not discuss other variables that may have impacted results.

METHODS

Chemical speciation of an element defines the oxidation state, concentration and composition of each species present in a given chemical, living or environmental sample [15].

Speciation by pH of zinc from lozenges allows the determination of each positively, neutrally and negatively charged species in aqueous solutions. When several complexes of a metal form in solution and the competition of metal hydroxides is not negligible, computations are used to determine the metal species present. These computations are complex and require the use of a computer, and are plotted graphically with results shown as metal species over a pH range.

Computed Speciations

The computations for each zinc lozenge formulation shown in Figs. 1–5 below were performed using an adapted version of the SPE computational program [16] which, for a maximum of two metal ions and two ligands, can accommodate all involved complex equilibria (i.e., ligand protonation, metal ion hydrolysis, metal-ligand complexation). Stoichiometric stability constants were selected from European [17] and American [18] databases.

The computed figures show the amount of positively charged zinc species, neutrally charged species and negatively charged species at each pH ($-\log[\text{H}^+]$) and the effects of confounding additives.




Fig. 1. Distribution (percentage) of zinc ionic species in the Zn^{2+} and gluconic acid system. Curves were constructed from pK values shown after the reactions: $Zn^{2+} + L^- \rightleftharpoons ZnL^+$ (1.62) and $ZnL^+ + OH^- \rightleftharpoons ZnL(OH)$ (8.14) at a concentration of 5 mmol zinc. The second pK value is courtesy of Gerritt Bekendam of Akzo Chemicals BV Research Centre, Deventer, The Netherlands (a ZG producer). The Zn^{2+} fraction over pH 6 is strongly affected by the second pK value. Data are shown at 5 mM ZG. iZn was 72% of total zinc.

Lozenge Chemical Stability and Bioavailability Criteria

Each zinc-ligand complex in lozenges has a unique chemical stability and bio-availability related to: (a) the strength of the ligand as a zinc ion binding agent, (b) the pH of the medium (Physiologic pH 7.4), (c) the molar concentration of zinc in saliva (calculated at 5 mM, which is representative of zinc lozenges in saliva), (d) body temperature, $37^\circ C$, and (e) confounding additives such as one or more zinc binding agents.

Effects of Confounding Additives

ZG and zinc acetate (ZA) have very low chemical stability and mainly release positively charged zinc ions in aqueous solutions at physiological pH, while stronger complexes do not. Adding a strong zinc binding ligand such as glycine or citric acid to a solution containing a zinc complex that is weakly bound results in the sequestration of zinc to the stronger ligand reducing or eliminating benefits. The effects on positively charged zinc by confounding additives (glycine and citric acid) are shown in Figs. 2, 3 and 5 and Table 1.

These computations do not take into account interaction of positively charged zinc with proteins, lipids and carbohydrates present in saliva and oral and nasal tissues. Although these interactions are important as shown by Bakar




Fig. 2. Distribution (percentage) of zinc ionic species in the 1:2 mole ratio ZG-glycinate system. Data is shown at 5 mM for ZG, and 10 mM for glycine. iZn is 57% of total zinc.




Fig. 3. Distribution (percentage) of zinc ionic species in the 1:10 mole ratio ZG-glycinate system. Data is shown at 5 mM for ZG and 50 mM for glycine. iZn is 11% of total zinc.




Fig. 4. Distribution (percentage) of Zn^{2+} ion in the zinc and acetate system by pH. Acetate protonation curves in the presence and absence of zinc were found to be exactly superimposable. Data are shown at 5 mM ZA concentration. iZn is 100% of total zinc.




Fig. 5. Distribution (percentage) of zinc ionic species in the ZG and excess citric acid system. Two negatively charged species exist at pH 7.4. Data are shown at 5 mM zinc and 6.5 mM citrate concentration. Speciation of zinc citrate is similar.

Table 1. Effect of Glycine on iZn from Cold-Eeze (ZG-glycinate) at 5 mmol ZG concentration

Molar ratio of ZG: glycine	iZn as percent of total zinc
1:0	72
1:2	57
1:4	32
1:6	20
1:8	14
1:10	11

et al. [7], they mainly result in a requirement for a much larger concentration (~700-fold) of positively charged zinc than would be required for biological effects *in vitro*.

iZn—The Sum of All Positively Charged Zinc Species at Physiologic pH 7.4

The sum of all positively charged zinc species for zinc compounds at physiologic pH 7.4 is termed iZn. These sums were manually added using pH 7.4 data in Figs. 1–5. These critical sums are expressed in milligram doses or as a fraction of total zinc. Daily iZn equals the number of daily doses multiplied by milligrams iZn per dose.

Without computations of iZn dosages, understanding the nature of the dose–response found in these trials, and the *a priori* prediction of efficacy or inefficacy from zinc lozenges on common cold duration, would not be possible. Vertically summed, data at each pH in Figs. 1–5 equals 100%. For purposes of common cold treatment with zinc lozenges, only positively charged zinc species at physiologic pH 7.4 (iZn) are biologically useful.

RESULTS

Re-analysis of these 12 reports is arranged by chemical composition of lozenges. Lozenges contained either: (a) ZG without confounding additives, (b) ZG with glycine, (c) ZA, or (d) other zinc compounds.

Zinc Gluconate

Zinc is lightly bound to gluconate (first stability constant is $\log K_1 = 1.70$) [19]. Figure 1 shows zinc species present at each pH in the zinc and gluconic acid system. At physiological pH 7.4, and 5 mM, ZG in solution releases 63% of zinc as Zn^{2+} ions and 9% as zinc gluconate¹⁺, totaling 72% as iZn. Neutrally charged ZG–hydroxide (28% of total zinc) is not useful in treating common colds, and may cross cell-plasma membranes becoming the source of oral irritation found using ZG lozenges.

The ZG compressed tablets used by Eby *et al.* [2] as lozenges contained 23 mg of zinc. From Fig. 1, they released 16.56 mg of iZn at physiologic pH 7.4. These slow-dissolving (about 30 min) lozenges were used each two wakeful hours (9 per day), with two lozenges (one after the other—not exceeding 12 lozenges) on day one of treatment as a loading dose. Daily iZn was 200 mg on day one, and after day one was 149 mg. Median duration of common colds was shortened by 4.8 days. The

mean duration of zinc-treated colds was 3.9 days, and 10.8 days for placebo-treated colds (difference = 7 days, $p < 0.0001$) These lozenges contained no carbohydrates and were not bitter, rather they were chalky and bland in taste.

The Al-Nakib *et al.* [3] ZG lozenges studied at the British MRC Common Cold Unit in Salisbury, England, also contained 23 mg of zinc, which released 16.56 mg iZn. Daily iZn was 149 mg. The formulation was a wet-granulated fructose-based compressed tablet made by RBS Pharma, Milan, Italy (now part of Rhône-Poulenc Pharma). The lozenges were used against human rhinovirus-2 induced colds. The lozenges dissolved in 20 min and were used every two wakeful hours (9 per day) for 6 days. The loading dose on the first day when viruses were most prevalent as used by Eby *et al.* [2] was not used. Total scores over the six-day trial of physician-observed common cold symptoms were 41.0 in the placebo-treated group and 27.2 in the zinc-treated group ($p < 0.05$) The average number of tissue papers used was 21.7 in the placebo-treated group and 14.3 in the zinc-treated group ($p < 0.01$) Nasal secretions averaged 51.4 g in the placebo-treated group and 22.0 g in the zinc-treated group ($p < 0.05$). Re-analysis of the MRC Figs. 1 and 2 demonstrated a 4.8 day mean difference between the zinc- and placebo-treated colds [4]. These lozenges were formulated with fructose and were not bitter, rather they were sweet, highly flavored and chalky in taste.

Smith *et al.* [20], using extremely bitter ZG lozenges (11.5 mg zinc—half the amount planned) in sucrose, mannitol and sorbitol lozenges and 11 other confounding ingredients, found no significant difference in median or mean duration of colds using lozenges nine times per day, although 12.6% fewer subjects using zinc on days 5 through 7 were sick ($p = 0.09$), and severity was reduced on days 5 through 7 ($p = 0.02$). Daily iZn was 74.5 mg. Similarly, with low dose, bitter ZG maltitol hard-boiled candy (4.5 mg zinc) lozenges, Weisman *et al.* [21] found no effect using lozenges 10 times a day. Daily iZn was 32.4 mg.

ZG with Glycine

ZG lozenges manufactured without dextrose-based carbohydrates are bland tasting and produce a tannic acid-like mouth feel. However, when carbohydrates (excluding fructose) are used in lozenges, a slow chemical reaction occurs, which over a few weeks to a few months time results in a change in flavor of ZG from bland to noisomely bitter. Consequently, some means of preventing this reaction was needed to produce pleasant tasting lozenges containing ZG.

Two to ten moles of glycine relative to ZG prevents the adverse flavor reaction according to US patent 4,684,528 licensed to the Quigley Corporation (Doylestown, PA), the manufacturer of Cold-Eeze brand zinc gluconate–glycine (ZGG) lozenges. However, wide variation in iZn attributable to different molar ratios of glycine to ZG in Cold-Eeze occurs, resulting in poor lozenge performance.

With 10 mol of glycine relative to one mole of ZG, iZn falls to 11% of total zinc, nearly eliminating iZn. With 2 mol of glycine per mole of ZG added, iZn falls only to 57% of total zinc. Consequently, either modest efficacy or inefficacy from Cold-Eeze results when different amounts of glycine are used.

Support for Table 1 is found in the above computations and similar intermediate computations (data not shown). Since the amount of glycine was not stated for any study of Cold-Eeze lozenges against common cold duration, and could have

been between two and ten moles relative to ZG according to the patent, the average amount was elected to calculate iZn, median and mean duration statistics.

Godfrey *et al.* [22] in 1992 tested 23.7 mg of zinc and 10 mol of glycine relative to zinc gluconate (ZGG) as flavor mask. These lozenges were used 7.1 times per day. Zinc was chelated away from gluconate by the much stronger binding agent, glycine ($\log K_1 = 4.8$) [23]. Glycine binds zinc tightly and releases positively charged Zn^{2+} ions only in acidity. From Fig. 3 (1:10 mol ratio ZG to glycine) at physiologic pH 7.4, positively charged zinc glycinate¹⁺ (iZn) is 11% of total zinc. Eighty-two percent of zinc at physiologic pH is neutrally charged. Daily iZn was 18.5 mg. Comparing mean duration of ZGG-treated colds to mean duration of colds treated with tannic acid, a reduction of 1.3 days was shown. However, this study seems to have incorrectly convinced many that ZGG treatment reduced colds by 42%. Oral side effects were stated as mild and not significantly different than placebo.

The first Cold-Eeze (13.3 mg zinc) study was the 1996 Cleveland Clinic study in adults led by Mossad [24]. Six lozenges were used per day. One half of all colds treated with zinc were over in 4.4 days compared with 7.6 days for placebo (3.2 day reduction $p < 0.001$). The mean duration of zinc-treated colds was 5.2 days compared with 9.3 days for placebo-treated colds (4.1 day, $p = 0.001$). Daily iZn was averaged at 27.2 mg.

The second Cold-Eeze (ZGG with 10 mg zinc) study was the no-effect 1998 Cleveland Clinic trial in children led by Macknin [25]. Lozenges were used six times per day. Daily iZn was averaged at 20.4 mg.

Turner and Cetnaroski [26] found in 2000 a one-half day increase in median duration using Cold-Eeze (ZGG with 13.3 mg zinc used six times a day) in adults with natural colds against tannic acid placebo, and a 1-day reduction in median duration in rhinovirus type-39 induced colds. Daily iZn was averaged at 27.2 mg.

The McElroy and Miller 2002 retrospective medical chart study [27] used common cold duration data from students not treated in 1998 compared with cold duration data collected in 1999 while using Cold-Eeze, reporting statistically significant efficacy (median duration 4-day difference and mean duration 1.5-day difference). This report was not a double-blind, placebo-controlled study and it presents some historically erroneous material [28]. Although this study is mentioned here for purposes of completeness, it was not further used in this re-analysis.

Zinc Acetate

Unlike ZG, ZA does not adversely react with sweet carbohydrates, and it has the extremely low first stability constant of $\log K_1 = 1.00$ [19, 29]. Hacht and Berthon [29] found that regardless of pH, Zn^{2+} ion concentration from solutions containing ZA is essentially 100% (see Fig. 4). According to US patent 5,095,035, Eby found pleasant tasting, flavor-stable ZA lozenges to be readily prepared. Oral irritation during common cold treatment using ZA lozenges is much lower than produced by ZG, perhaps because the cytotoxic neutral zinc species found in ZG solutions are absent. Action of ionic zinc occurs extracellularly on the cell membrane where it increases cell membrane stability and prevents toxic influx of zinc into cells [13] and may inhibit the action of ICAM-1 [14].

Using ZA lozenges, Petrus *et al.* [30] in 1998, found significant reductions in mean duration (3.8 days zinc, 5.1 days placebo, for a 1.8 days difference $p = 0.008$) and reductions in severity of common colds using 9 mg of zinc in 2.7-g dextrose based lozenges. Lozenges were used each 1.5 hr on the first day and every 2 hr on following days during wakeful hours (8 per day). Lozenges dissolved in about 15 min. Daily iZn was 72 mg. Petrus also found that ZA lozenges relieved nasal symptoms much faster in common cold patients with a history of allergy, but without active allergy symptoms, compared with allergy-negative subjects (0.8 days vs. 4.1 days $p < 0.04$).

Prasad *et al.* [12] in 2000, found meaningful and significant efficacy using 12.8 mg zinc (ZA) in 4.0 g lozenges. Lozenges were used each 2–3 hr (6.25 per day) and they dissolved in about 30 min. iZn was 80 mg. Fifty percent of zinc recipients were well in 3.8 days and 50% of placebo recipients were well in 7.7 days (3.9 days difference). The zinc group had shorter mean durations of colds (4.5 vs. 8.1 days $p < 0.01$, a 3.6 day reduction), decreased total severity scores for all symptoms with good placebo blinding, mild or no side effects and little difference in side effects compared with mild tasting placebo. The effect was sufficiently strong that Prasad suggested seeing a physician for a bacterial infection if symptoms were not significantly improved after using ZA lozenges for 3 days.

The Petrus and Prasad compressed lozenges were designed by the present author and were identical in composition. In addition to ZA, they contained directly compressible (agglomerated) dextrose as the tablet base, glycerol mono-stearate (2.5% tablet weight) as tablet lubricant, *stevia* for added sweetness and peppermint oil for flavor, with the composition compressed to near maximal hardness for slowest dissolution. Those ingredients were chosen specifically because they do not react with iZn. The slower dissolution of the 4-g size lozenges was an advantage over the smaller lozenges in terms of efficacy.

OTHER ZINC COMPOUNDS

Several trials used other food acids to flavor-mask the bitter ZG/dextrose reaction, resulting in loss of efficacy. The negative study by Farr and Gwaltney [31] used 23 mg zinc (ZG) with citric acid ($\log K_1 = 4.7$) at a 1:1.3 molar ratio of ZG to citric acid [32]. These ZG–citrate (ZG-C) lozenges lengthened mean duration of common colds by 1 day. Negatively charged zinc species from these lozenges at physiologic pH 7.4 (see Fig. 5) could be expected to lengthen colds only if positively charged zinc ions (perhaps from mast cells lining the interior of the nose) have a natural role in terminating common colds and become neutralized by negatively charged zinc. iZn was negative.

Douglas *et al.* [33] in 1987 demonstrated lack of efficacy using 10 mg zinc lozenges 6 times a day [ZA with extramolar tartaric acid reacting with sodium bicarbonate—(ZA-TB)] as described in a letter to R.M. Douglas from R.J.E. Williams forwarded to this author [4] to produce strong oral effervescence. In the effervescent process, iZn was eliminated. Zinc species were negatively charged at physiologic pH by excess tartaric acid ($\log K_1 = 5.0$) [34]. Colds were lengthened by 4.4 days. iZn was negative.

Eby [35] in 2001 reported additives (molar excesses of stearate, oleate and palmitate) cooked in 5 mg and 11.5 mg Halls Zinc Defense hard-boiled candy

lozenges (ZA-SOP) used 6 times per day eliminated ionic, soluble and nutritive zinc from ZA resulting in null effects in the Turner and Cetnaroski trial [26]. iZn was 0 mg. In unpublished studies zinc aspartate and zinc orotate lozenges, both too tightly bound to release iZn, failed to show efficacy.

Data Summary

The above re-analyses of 12 published reports provides data for use in Table 2. This data is further analyzed to determine statistical relationships between total daily zinc and daily iZn and resultant reductions in duration of median and mean durations of common colds using zinc lozenges having greatly different chemical properties. Results are shown in Fig. 6. Cold-Eeze lozenge iZn dosages were calculated at 50% of their possible range, but other fractions in their range can be calculated using Fig. 6 if desired without significant change in outcome.

Statistics

Considering only the total amount of zinc taken per day without regard to charge, statistical significance is shown for reduction in median duration ($n = 12$, $r = 0.699$, $p < 0.01$); but not for mean duration ($n = 9$, $r = 0.599$, $p < 0.12$).

Statistical significance was found for daily iZn and both median and mean durations of colds. Statistical significance was declared if the two-sided p value was ≤ 0.05 . Values for Pearson correlation (r) and p were determined using the Vassar Stats Linear Correlation and Regression Direct-Entry on-line program (http://faculty.vassar.edu/lowry/corr_stats.html).

Analysis shows statistically significant relationship of daily iZn and reductions in duration of common colds. Table 2 and Fig. 6 show that daily iZn dosage is directly associated with reductions in durations of colds by two measures, median ($n = 12$, $r = 0.754$, $p = 0.005$) and mean ($n = 10$, $r = 0.727$, $p < 0.02$) durations. The hypothesis that there is a positive correlation between intra-oral daily iZn dosage and reduction in duration of common colds was statistically confirmed by these two measures. Reduction in duration of colds from intra-oral iZn dosage occurs in a dose-response manner.

DISCUSSION

Analyses of lozenge compositions using solution chemistry methods allows the valid determination of zinc ionic species at physiologic pH 7.4. iZn at physiologic pH 7.4 varied from 0 to 100% in lozenges, producing a related dose-response. Neutrally charged zinc had no effect on colds. Negatively charged zinc worsened colds.

The highly meaningful 7-day reduction in mean duration results of Eby [2] and the 4.8 day reduction in mean duration of Al-Nakib [3] were not obtained in other studies because other researchers did not use lozenges having daily iZn doses greater than one-half the doses used by either Eby or Al-Nakib.

Although the exact means by which iZn reduces durations of common colds remains to be determined, this writer believes that the effects occur at the cell

Table 2. Effects of Total Zinc and Daily iZn on Common Cold Median and Mean Durations

Trial	Zinc compound	Zinc per lozenge (mg)	Lozenges per day	Total daily zinc (mg)	Fraction of total zinc as iZn (%)	Daily iZn (mg)	Reduction in median duration (days)	Reduction in mean duration (days)
Eby (Ref. 2)	ZG	23	9	207	72	149	4.8	7
Al-Nakib (Ref. 3)	ZG	23	9	207	72	149	n.a.	4.8
Prasad (Ref. 12)	ZA	12.8	6.25	80	100	80	3.9	3.6
Smith (Ref. 20)	ZG	11.5	9	103.5	72	74.5	0	0
Petrus (Ref. 30)	ZA	9.0	8	72	100	72	n.a.	1.8
Petrus (Ref. 30 allergy)	ZA	9.0	8	72	100	72	n.a.	3.3
Weisman (Ref. 21)	ZG	4.5	10	45	72	32.4	0	0
Mossad (Ref. 24)	ZGG	13.3	6	80	11-57 (ave. 34)	8.8-45.6 (ave. 27.2)	3.2	4.1
Turner (Ref. 26 natural colds)	ZGG	13.3	6	80	11-57 (ave. 34)	8.8-45.6 (ave. 27.2)	1	n.a.
Mackinn (Ref. 25)	ZGG	10.0	6	60	11-57 (ave. 34)	6.6-34.2 (ave. 30.4)	0	0
Godfrey (Ref. 22)	ZGG	23.7	7.1	168	11	18.5	n.a.	1.3
Turner (Ref. 26 natural colds)	ZA-SOP	5.0	6	30	0	0	-0.5	n.a.
Turner (Ref. 26 induced colds)	ZA-SOP	5.0	6	30	0	0	0	n.a.
Turner (Ref. 26 natural colds)	ZA-SOP	11.5	6	69	0	0	0	n.a.
Turner (Ref. 26 induced colds)	ZA-SOP	11.5	6	69	0	0	n.a.	-1
Douglas (Ref. 33)	ZA-TB	10	6	60	Negative	Negative	n.a.	-4.4

n.a. = not available.




Fig. 6. (a) Effect of daily iZn on reduction in mean duration of common colds in days ($n = 12$, $r = 0.754$, $p < 0.005$). (b) Effect of daily iZn on reduction in mean duration of common colds in days ($n = 10$, $r = 0.727$; $p < 0.02$).

membrane, either by direct membrane protection as suggested by Pasternak [13] and/or by ICAM-1 inhibition on the cell membrane as suggested by Novick [14].

Two data pairs [31, 33] having negatively charged zinc at physiologic pH 7.4 could not be used in computing statistics because no reliable analytical method for determining negative iZn is known.

Computation of results using molar concentrations of glycine other than the average values chosen for this analysis does not vary the overall results.

Taste problems and oral irritation using ZG caused most if not all of the problems found in commercializing zinc lozenges for colds. To reduce or eliminate the ZG/dextrose reaction and oral irritation, some manufacturers either used low amounts of ZG or added strong zinc binding agents, which reduced or eliminated efficacy.

Although pure ZG is bland and chalky in taste, it reacts with dextrose and related carbohydrates (excluding fructose) upon aging of lozenge compositions to

produce noisome bitterness and compliance-related inefficacy. ZG releases large amounts of neutrally charged hydroxide species likely to cross cell membranes and causes oral irritation. Bitterness occurs in all ZG lozenges except those that either do not contain carbohydrates (excluding fructose), or that contain strong extramolar zinc binding agents, which results in something other than ZG. For these reasons, ZG is no longer believed suitable for use in zinc lozenges for treating colds.

On the other hand, ZA allows the production of pleasant tasting, flavor stable lozenges releasing large amounts of iZn either in hard candies or compressed tablets without flavor or stability issues. The mouth-feel produced is sufficiently like the mouth-feel of tea (slight astringency) to allow using tannic acid without added bitter agents as a placebo in clinical trials.

A larger correlation between iZn and efficacy can be obtained by also considering lozenge oral dissolution times, and saliva production during oral dissolution of lozenges, in accordance with Fick's laws of membrane permeability [4]. However, these considerations require extensive laboratory knowledge of lozenge properties.

The iZn method of analysis explains most variations from expectations using slow dissolving lozenges. Poor compliance when using bitter lozenges as shown by Smith *et al.* [20] further explains negative results. However, iZn calculations do not explain highly efficacious results of trials where lozenges have low daily iZn doses. The Mossad lozenges were very early Cold-Eeze, and there may have been much less glycine (perhaps a 1 to 1 molar ratio) in these lozenges than in more recently produced and relatively ineffective Cold-Eeze lozenges, explaining observed efficacy.

In studies mainly of Cold-Eeze showing non-meaningful effects, the one day improvements in duration may have resulted from improved primary immunocompetence by nutritional support resulting from swallowed zinc, which amounted to 80 mg zinc per day in adults. Nutrients such as vitamin C and zinc are required by the primary immune system, and correction of their dietary insufficiencies have been shown to improve immune function, reduce recovery time, help prevent diarrhea and pneumonia [36], help lower use of antibiotics and help prevent other colds [27]. T-cell lymphocyte immunologic benefit from supplemental zinc in the 100–150 mg/day range has been shown [37, 38]. However, T-cell activity has been shown to be temporarily impaired by administration of 300 mg zinc/day for 30 days [39].

In these trials different lozenges produced zinc salivary concentrations that varied from about 1 mM to about 8 mM. In this re-analysis solution chemistry computations were performed at 5 mM, a concentration that accurately represents this range.

The each two-hour protocol used by Eby [2] and others was used because rhinoviral replication increases 100-fold in 24 hr, and because common cold symptoms seem to return in two-hours intervals while using zinc lozenges empirically suggesting that frequent treatment is needed. Treatment frequency varied somewhat between the 12 trials studied. There was no statistical significance detected between frequency of administration and reductions in durations of colds in these trials. To detect any statistical significance here would require numerous clinical trials of a single composition, not the multiple, highly different compositions reviewed here.

Turner [40] questioned the rationale for intra-oral administration of zinc rather than intranasal zinc. Intra-oral administration can be seen as the proper means of administration only when one considers biophysical effects. In partial answer to Turner's question, Nordenström extensively and thoroughly documented long-range biologically closed electric circuits (BCEC) in humans in 1983 [41].

More completely answering Turner's question, a mouth–nose BCEC was described by Eby [4]. The mouth–nose BCEC can be observed by placing a lead of a digital voltmeter in the mouth and the other lead in the nasal cavity. This circuit has been shown to produce a 60–120 mV potential difference [4]. In treatment of colds with zinc lozenges, this writer believes that electrons from the mouth–nose BCEC transport iZn from the mouth into the nasopharyngeal and nasal tissues in much the same way that electrons corrode metal away from an electric battery terminal. Neutrally and negatively charged zinc species from the mouth are not transported by the BCEC into nasal–pharyngeal or nasal tissues. Even if they were, they have no known biological function in treating colds.

On the other hand, positively charged substances, such as zinc ions, applied on top of the nasal mucous are repelled by electrons flowing from the mouth outward through the nasal and nasal pharyngeal tissues, causing them to be expelled by the mucous and down into the throat. The mouth–nose BCEC also suggests no possibility for meaningfully reducing the duration of colds using intra-nasal zinc without electricity to reverse the mouth–nose BCEC.

In 1931, reversing the mouth–nose BCEC using intra-nasally applied direct current with zinc sulfate soaked nasal packings resulted in very long lasting (1 year) benefits in the treatment of rhinitis [42]. Application of voltage also produced an instant taste of zinc sulfate in the mouth, showing the ready movement of iZn electrically between the mouth and nose.

People immune to colds have a mouth–nose electrical resistance of over 100 kohms, while people susceptible to colds have resistances less than one-fifth that value [4].

Various compounds of zinc were used intra-nasally from 1901 to 1938 in the treatment of rhinitis and picornavirus infections [42, 43]. In 1938, intra-nasal 1% zinc sulfate was reported to cause anosmia in about one-quarter of the children treated, and was thereafter discontinued [44]. Eby and Halcomb found no reduction in duration of common colds using 10 mM ZG nasal sprays used aggressively each 15–30 min [4]. Reduction in duration of colds by intra-nasal zinc was not shown until 2000, when Hirt *et al.* reported 33 mmol/l ZG nasal gel to meaningfully shorten colds [45], with null [40] and limited [46] results, and anosmia [47] being later reported.

ZA lozenges have more utility than only treating rhinovirus common colds. Herpes viruses are also controlled by iZn [48, 49]. ZA lozenges have been useful in treating oral, lip and nasal herpes infections with benefit, including reducing occurrence and duration of outbreaks. In one child and one adult (the only cases known), 14.2 mg zinc (ZA) lozenges used each wakeful hour (daily $iZn = 200$ mg) terminated all mononucleosis (Epstein Barr virus) symptoms in 3 days without relapse, sequela or side effects [4].

Although these trials, with the exception of the Macknin trial with low dose Cold-Eeze [25], did not study the effect of zinc lozenges in children, the original

discovery occurred in a 3-year old leukemic child with complete elimination (without relapse) of all common cold symptoms in about 2 hrs using a single 50-mg zinc (ZG) tablet as a throat lozenge while napping [2, 4]. Consequently, these beneficial effects using lozenge protocols having a high daily iZn dose (for example 142 mg iZn–14.2 mg iZn doses used 10 times per day) should produce an equal or better response in children than occurred in adults in these trials without significant side effects.

Sleeping slows or stops lymphatic drainage of zinc and should accelerate recovery, consequently, the bedtime dosages used by Eby and others are important. Similarly, napping after administration of doses is beneficial.

Carbohydrates generally do not impair release of iZn from lozenges [50]. Equivalent dosage hard-boiled candy (corn syrup and sugar) lozenges can produce results similar to compressed tablets. However, some compositions may require additional ZA for identical efficacy due to more rapid dissolution and increased saliva production from use of a hard candy base. Use of a honey–lemon candy base introduces gluconate, which adversely affects taste, while lemon juice solids (mainly citric acid) eliminate both efficacy and gluconate taste.

Daily iZn doses in future trials should be 200 mg on the first day of treatment, and 100–150 mg on following days to obtain 7-day reductions in duration of colds. During the first day, lozenges may be used more often than each 2 hrs, and two lozenges at a time may be used. These dosages are achievable using 14.2 mg zinc (from 40 mg ZA anhydrous) in maximally compressed 4-g dextrose with 2.5% glycerol monostearate as tablet lubricant lozenge. From this review, daily iZn doses less than 75 are much more like candy than medicine.

In order to determine the relative and absolute efficacy of zinc lozenges for common colds, additional research—preferably multi-center trials—using ZA lozenges (14.2 mg zinc—available from the author) compared with both Cold-Eeze ZGG lozenges (available from the Quigley Corporation, Doylestown, PA) and tannic acid placebo used 7–14 times per day are suggested against rhinovirus, herpesvirus, and coronavirus upper respiratory infections and mononucleosis.

ACKNOWLEDGMENTS

Many thanks are extended to Dr. Guy Berthon, retired Directeur de Recherche au Centre National de la Recherche Scientifique, Equipe de Chimie Bioinorganique Médicale, Université Paul Sabatier, Toulouse, France, for freely given determinations of the solution chemistry of zinc lozenge compositions, professional and moral encouragement. Without his kind and endless support, this re-analysis could not have been prepared, and the confounding effects of flavor additives responsible for reduction or elimination of efficacy in some of these clinical trials could not have been elucidated.

REFERENCES

1. Winther, B., Gwaltney, J. M., Mygind, N., Turner, R. B., and Hendley, J. O. (1986) Sites of rhinovirus recovery after point inoculation of the upper airway. *JAMA* **256**:1763–1767.
2. Eby, G. A., Davis, D. R., and Halcomb, W. W. (1984) Reduction in duration of common colds by zinc gluconate lozenges in a double blind study. *Antimicrob. Agents Chemother.* **25**:20–24.

3. Al-Nakib, W., Higgins, P. G., Barrow, I., Batstone, G., and Tyrell, D. A. (1987) Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. *J. Antimicrob. Chemother.* **20**:893–901.
4. Eby, G. A. (1994) *Handbook for Curing the Common Cold—The Zinc Lozenge Story*, George Eby Research, Austin (<http://coldcure.com/html/handbook-for-curing-the-common-cold.html>).
5. Eby, G. A. (1997) Zinc ion availability—the determinant of efficacy in zinc lozenge treatment of common colds. *J. Antimicrob. Chemother.* **40**:483–493.
6. Eby, G. A. (1995) The Zinc lozenge and common cold story. In: *Metal-Ligand Interactions in Biological Fluids: Bioinorganic Medicine*, Vol. 2, Marcel Dekker, Inc., New York, pp. 1182–1190.
7. Bakar, N. K. A., Taylor, D. M., and Williams, D. R. (1999) The chemical speciation of zinc in human saliva: possible correlation with reduction of the symptoms of the common cold produced by zinc gluconate-containing lozenges. *Chem. Speciat. Bioavailab.* **11**:95–101.
8. Jackson, J. L., Lesho, E., and Peterson, C. (2000) Zinc and the common cold: a meta-analysis revisited. *J. Nutr.* **130**:1512S–1515S.
9. Jackson, J. L., Peterson, C., and Lesho, E. (1997) A meta-analysis of zinc salts lozenges and the common cold. *Arch. Int. Med.* **157**:2373–2376.
10. Macknin, M. L. (1999) Zinc Lozenges for the common cold. *Cleve. Clin. J. Med.* **66**:27–32.
11. Korant, B. D., Kaurer, J. C., and Butterworth, B. E. (1974) Zinc ions inhibit replication of rhinoviruses. *Nature(London)* **248**:588–590.
12. Prasad, A. S., Fitzgerald, J. T., Bao, B., Beck, F. W. J., and Chandrasekar, P. H. (2000) Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate. a randomized, double-blind, placebo-controlled trial. *Ann. Int. Med.* **133**:245–252.
13. Pasternak, C. A. (1987) A novel form of host defense: membrane protection by calcium and zinc ions. *Biosci. Rep.* **7**:81–91.
14. Novick, S. G., Godfrey, J. C., Pollack, R. L., and Wilder, H. R. (1997) Zinc-induced suppression of inflammation in the respiratory tract, caused by infection with human rhinovirus and other irritants. *Med. Hypotheses* **49**:347–357.
15. Taylor, D. M. and Williams, D. R. (1995) *Trace Element Medicine and Chelation Therapy*, The Royal society of Chemistry, Cambridge, p. 63.
16. Martell, A. E. and Motekaitis, R. J. (1988) *Determination and Use of Stability Constants*. VCH, Weinheim, Germany.
17. Pettit, L. D. and Powell, K. J. (1997) *The IUPAC Stability Constants Database*. Academic Software, Otley, UK.
18. Smith, R. M., Martell, A. E. and Motekaitis, R. J. (1995) *NIST Critically Selected Stability Constants of Metal Complexes Database*, Version 2, US Department of Commerce, NIST, Gaithersburg, MD.
19. Cannan, R. K. and Kibrick, A. (1938) Complex formation between carboxylic acids and divalent metal cations. *Am. Chem. Soc.* **60**:2314–2320.
20. Smith, D. S., Helzner, E. C., Nuttall, C. E. Jr., Collins, M., Rofman, B. A., Ginsberg, D., Goswick, C. B. and Magner, A. (1989) Failure of zinc gluconate in treatment of acute upper respiratory tract infections. *Antimicrob. Agents Chemoth.* **33**:646–648.
21. Weismann, K., Jakobsen, J. P., Weismann, J. E., Hammer, U. M., Nyholm, S. M., Hansen, B., Lombolt, K. E., and Schmidt, K. (1990) Zinc gluconate for common cold. *Dan. Med. Bull.* **37**:279–281.
22. Godfrey, J. C., Conant Sloane, B. and Smith, D. S. (1992) Zinc gluconate and the common cold. *J. Int. Med. Res.* **20**:234–246.
23. Alemdaroglu, T. and Berthon, G. (1981) Trace metal requirements in total parenteral nutrition II. Potentiometric study of the metal-ion equilibria in the zinc-histidine, zinc-glycine, zinc-cysteine–histinidine, zinc-glycine–histidine and zinc-glycine–cysteine systems under physiological conditions. *J. Electroanal. Chem. and Interfacial Electrochem.* **128**:49–62.
24. Mossad, S. B., Macknin, M. L., Medendrop, S. V., and Mason, P. (1996) Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study. *Ann. Int. Med.* **125**:81–88.
25. Macknin, M. L., Piedmonte, M., Calendine, C., and Janosky, W. E. (1998) Zinc gluconate lozenges for treating the common cold in children: a randomized controlled trial. *JAMA* **279**:1962–1967.
26. Turner, R. B. and Cetnarowski, W. E. (2000) Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds. *Clin. Infect. Dis.* **31**:1202–1208.

27. McElroy, B. H. and Miller S. P. (2002) Effectiveness of zinc gluconate glycine lozenges (Cold-Eeze[®]) against the common cold in school-aged subjects: a retrospective chart review. *Am. J. Ther.* **9**:472–475.
28. Eby, G. A. (2003) Cold-Eeze lozenge for common colds. *Am. J. Ther.* **10**:233.
29. Hacht, B. and Berthon, G. (1987) Metal ion-FTS nonapeptide interactions. A quantitative study of zinc(II)-nonapeptide complexes (thymulin) under physiological conditions and assessment of their biological significance. *Inorganica. Chimica. Acta.* **136**:165–171.
30. Petrus, E. J., Lawson, K. A., Bucci, L. R. and Blum, K. (1998) Randomized, double-masked, placebo-controlled, clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects. *Curr. Ther. Res.* **59**:595–607.
31. Farr, B. M., Conner, E. M., Betts, R. F., Oleske, J., Minnefor, A. and Gwaltney, J. M. Jr. (1987) Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. *Antimicrob. Agents Chemother.* **31**:1183–1187.
32. Martin, R. B. (1988) pH as a variable in free zinc ion concentration from zinc-containing lozenges. *Antimicrob. Agents and Chemother.* **32**:608–609.
33. Douglas, R. M., Miles, H. B., Moore, B. W., Ryan, P. and Pinnock, C. B. (1987) Failure of efferescent zinc acetate lozenges to alter the course of upper respiratory tract infections in Australian adults. *Antimicrob. Agents Chemother.* **31**:1263–1265.
34. Berthon, G., Varsamidis, A., Blaquiere, C. and Rigal, D. (1987) Histamine as a ligand in blood plasma. Part 7. Malate, malonate, maleate and tartrate as adjuvants of zinc to flavor histamine tissue diffusion through mixed-ligand coordination. *In vitro* tests on lymphocyte proliferation. *Agents Actions* **22**:231–247.
35. Eby, G. A. (2001) Elimination of efficacy by additives in zinc acetate lozenges for common colds. *Clin. Infect. Dis.* **32**:1520.
36. Bhutta, Z. A., Black, R. E., Brown, K. H., Gardner, J. M., Gore, S., Hidayat, A., Khatun, Martorell, F., R., Ninh, N. X., Penny, M. E., Rosado, J. L., Roy, S. K., Ruel, M., Sazawal, S. and Shankar, A. (1999) Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. *J. Pediatr.* **135**:689–697.
37. Duchateau, J., Delepesse, G., Vrijens, R. and Collet, H. (1981) Beneficial effects of oral zinc supplementation on the immune response of old people. *Am. J. Med.* **70**:1001–1004.
38. Duchateau, J., Delepesse, G. and Vereecke, P. (1981) Influence of oral zinc supplementation on the lymphocyte response of mitogens of normal subjects. *Am. J. Clin. Nutr.* **34**:88–93.
39. Chandra, R. K. (1984) Excessive intake of zinc impairs immune responses. *JAMA* **252**:1443–1446.
40. Turner, R. B. (2001) Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. *Clin. Infect. Dis.* **33**:1865–1870.
41. Nordenström, B. E. (1983) *Biologically Closed Electric Circuits. Clinical, Experimental and Theoretical Evidence for an Additional Circulatory System.* Nordic Medical Publications, Stockholm.
42. Franklin, P. (1931) Treatment of hay fever by intranasal zinc ionization. *BMJ* **1115**–1116.
43. Merck (1901) *Manual of the Materia Medica*, Part II, Formulas, Merck, New York, p. 125.
44. Tisdall, F. F., Brown, A. and Defries, R. D. (1938) Persistent anosmia following zinc sulphate nasal spraying. *J. Pediatr.* **13**:60–62.
45. Hirt, M., Nobel, S., and Barron, E. (2000) Zinc nasal gel for the treatment of common cold symptoms: a double-blind, placebo-controlled trial. *ENT* **79**:778–80, 82.
46. Mossad, S. B. (2003) Effect of zincum gluconicum nasal gel on the duration and symptom severity of the common cold in otherwise healthy adults. *QJM* **96**:35–43.
47. DeCook, C. A. and Hirsch, A. R. (2000) Anosmia due to inhalational zinc: a case report. *Chem Senses* **25**:659.
48. Arens, M. and Travis S. (2000) Zinc salts inactivate clinical isolates of herpes simplex virus *in vitro*. *J. Clin. Microbiol.* **38**:1758–1762.
49. Eby, G. A. and Halcomb, W. W. (1985) Use of topical zinc to prevent recurrent herpes simplex infection: review of literature and suggested protocols. *Med. Hypotheses* **17**:157–165.
50. Briggs, J., Finch, P., Matulewicz, M. C., and Weigel, H. (1981) Complexes of copper(II), calcium, and other metal ions with carbohydrates: thin-layer ligand-exchange chromatography and determination of relative stabilities of complexes. *Carbohydr. Res.* **97**:181–188.